ABEO — Abeona Therapeutics Inc. stock price, charts and financials

Latest market price

6.82

+0.43+6.73%

Overview Short InterestFilings

ABEOQT65Abeona Therapeutics Inc.·NASDAQ

Overview Short InterestFilings

6.82+6.73%

News

Up 6.7% — Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule (Benzinga).

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	5.00	EPS (ttm)	-214.81	Insider Own	-	Shs Outstand	57.00M	Perf Week	13.29%

Market Cap	388.71M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	-0.92%	Shs Float	36.62M	Perf Month	8.08%

Enterprise Value	242.71M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	36.14%	Perf Quarter	14.62%

Income	-2.00M	P/S	97.18	EPS this Y	99.65%	Inst Trans	-	Short Ratio	11.13	Perf Half Y	31.91%

Sales	4.00M	P/B	2.68	EPS next Y	90.65%	ROA	33.32%	Short Interest	13.23M	Perf YTD	29.41%

Book/sh	2.54	P/C	2.31	EPS next 5Y	-	ROE	41.40%	52W High	7.54 -9.55%	Perf Year	5.08%

Cash/sh	2.95	P/FCF	-	EPS past 3/5Y	-	ROIC	-50.87%	52W Low	4.00 70.50%	Perf 3Y	93.20%

Dividend Est.	-	EV/EBITDA	4.46	Sales past 3/5Y	81.71% -9.71%	Gross Margin	51.93%	Volatility	4.89% 5.29%	Perf 5Y	-78.18%

Dividend TTM	-	EV/Sales	60.68	EPS Y/Y TTM	-13758.71%	Oper. Margin	-637.92%	ATR (14)	0.33	Perf 10Y	-89.30%

Dividend Ex-Date	Mar 31, 2000	Quick Ratio	5.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.25	Recom	2.33

Dividend Gr. 3/5Y	-	Current Ratio	5.89	EPS Q/Q	-25.00%	SMA20	2.85%	Beta	1.31	Target Price	17.00

Payout	0.00%	Debt/Eq	0.15	Sales Q/Q	-	SMA50	12.00%	Rel Volume	0.98	Prev Close	6.39

Employees	226	LT Debt/Eq	0.08	Earnings	Aug 13	SMA200	27.95%	Avg Volume	1.24M	Price	6.82

IPO Date	Sep 19, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.45% 90.72%	Net Debt/EBITDA	-0.52	Volume	1,218,192	Change	6.73%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-17-26	Reiterated	Stifel Nicolaus		$20 → $17
May-16-25	Reiterated	Stifel Nicolaus		$21 → $20
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Nov-14-22	Reiterated	Leerink Partners		$6.00
Nov-30-21	Downgrade	SVB Leerink	Outperform → Market Perform
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-26-19	Downgrade	Mizuho	Buy → Neutral

Latest News

Aug-04-26

Aug-04-2607:37AM

Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final RuleBenzinga

07:30AM

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®globenewswire.com

Aug-03-26

Aug-03-2607:30AM

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-27-26

Jul-27-2608:30AM

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)prnewswire.com

Jul-21-26

Jul-21-2607:37AM

Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis BullosaBenzinga

07:30AM

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®globenewswire.com

Jul-01-26

Jul-01-2607:30AM

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Company

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	4	6	0	4	1	3	10	0	3
Cost of Goods Sold Incl. D&A	0	2	3	2	0	0	0	49	39
Gross Profit	4	4	-3	2	1	3	10	-49	-36
Selling, General and Administrative Excl. Other	5	65	30	19	17	22	24	21	20
Research and Development	1	27	34	31	29	39	30	54	39
Other Operating Expense	2	2	-3	-1	6	32	37	-46	2
Operating Income	-4	-89	-64	-47	-51	-90	-81	-77	-58
Interest Expense	0	4	4	0	1	4	4	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	3	164	5	-7	12	9	1	1	2
Net Income Before Taxes	-2	71	-64	-54	-40	-85	-84	-76	-57
Income Taxes	-30	0	0	0	0	0	0	0	0
Consolidated Net Income	-2	71	-64	-54	-40	-85	-84	-76	-57
Net Income From Continuing Operations	-2	71	-64	-54	-40	-85	-84	-76	-57
Net Income	-2	71	-64	-54	-40	-85	-84	-76	-57
EPS (Recurring)	-202.31	1.34	-1.55	-2.53	-5.53	-21.50	-22.75	-38.07	-29.81
EPS (Basic, Before Extraordinaries)	-202.31	1.34	-1.55	-2.53	-5.53	-21.50	-22.75	-38.07	-29.81
EPS (Diluted)	-214.81	1.01	-1.55	-2.53	-5.53	-21.50	-22.75	-38.07	-29.81
EBITDA	-27	79	-57	-51	-34	-77	-75	-69	-54
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	5.22	—	—	—	—	—	—	—
Price To Sales Ratio	—	46.55	—	26.30	24.64	11.33	15.70	—	119.00
Gross Margin	100.00	66.67	—	50.00	100.00	100.00	100.00	—	-1,200.00
Operating Margin	-100.00	-1,483.33	—	-1,175.00	-5,100.00	-3,000.00	-810.00	—	-1,933.33
Net Margin	-50.00	1,183.33	—	-1,350.00	-4,000.00	-2,833.33	-840.00	—	-1,900.00
Shares Outstanding	0	53	41	21	8	4	4	2	2
Market Capitalization	—	279	228	105	25	34	157	164	357
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vazzano Joseph Walter	Chief Financial Officer	Jul 21 '26	Sale	6.53	1,478	9,651	492,079	Jul 22
O'Malley Brendan M.	SVP, Chief Legal Officer	Jul 09 '26	Sale	6.96	12,050	83,913	427,953	Jul 09
Vasanthavada Madhav	Chief Commercial Officer	Jul 09 '26	Sale	6.96	12,606	87,784	290,623	Jul 09
Vazzano Joseph Walter	Chief Financial Officer	Jul 09 '26	Sale	6.96	24,880	173,257	493,557	Jul 09
Seshadri Vishwas	Chief Executive Officer	Jul 09 '26	Sale	6.96	67,971	473,330	1,306,108	Jul 09
Alland Leila	Director	Jun 30 '26	Sale	5.92	11,000	65,087	162,614	Jul 02
Silverstein Christine Berni	Director	Jun 15 '26	Sale	5.71	18,160	103,695	119,562	Jun 15
Seshadri Vishwas	Chief Executive Officer	Jun 09 '26	Sale	5.30	31,916	169,289	1,374,079	Jun 09
O'Malley Brendan M.	SVP, Chief Legal Officer	Jun 09 '26	Sale	5.30	6,305	33,443	440,003	Jun 09
Vazzano Joseph Walter	Chief Financial Officer	Jun 09 '26	Sale	5.36	39,067	209,476	518,437	Jun 09
Vasanthavada Madhav	Chief Commercial Officer	Jun 09 '26	Sale	5.30	5,450	28,908	303,451	Jun 09
Seshadri Vishwas	Chief Executive Officer	Jun 08 '26	Sale	5.43	24,428	132,632	1,405,995	Jun 09
O'Malley Brendan M.	SVP, Chief Legal Officer	Jun 08 '26	Sale	5.43	4,826	26,203	446,308	Jun 09
Vasanthavada Madhav	Chief Commercial Officer	Jun 08 '26	Sale	5.43	4,170	22,641	308,901	Jun 09
Vazzano Joseph Walter	Chief Financial Officer	Jun 08 '26	Sale	5.43	10,271	55,766	557,504	Jun 09

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.